RAD001 is active and well tolerated in relapsed NHL

Article

In aggressive, relapsed non-Hodgkin’s lymphoma, the oral investigational mTOR inhibitor RAD001 (everolimus) has single-agent activity and is well-tolerated for long periods, according to interim results of a phase II study presented at ASH 2007 (abstract 121). Craig B. Reeder, MD, of the Mayo Clinic, Scottsdale, Arizona, reported the results of the Mayo Clinic/Dana-Farber Cancer Institute trial (MAYO-MC048G)

ATLANTA-In aggressive, relapsed non-Hodgkin’s lymphoma, the oral investigational mTOR inhibitor RAD001 (everolimus) has single-agent activity and is well-tolerated for long periods, according to interim results of a phase II study presented at ASH 2007 (abstract 121). Craig B. Reeder, MD, of the Mayo Clinic, Scottsdale, Arizona, reported the results of the Mayo Clinic/Dana-Farber Cancer Institute trial (MAYO-MC048G).

Eligible patients had aggressive histologies, including diffuse large B-cell lymphoma (DLBCL) (54%), mantle cell lymphoma (MCL) (38%), and grade 3 follicular lymphomas. The patients had received a median of 4 prior therapies, with as many as 15. They received RAD001 at 10 mg/d on days 1 to 28 for up to 12 courses.

With patients having received a median of 2 cycles of RAD001 (range, 1 to 16+), the overall response rate was 32% (12 of 37 patients). Responses included 1 complete and 11 partial responses. The response rates for DLBCL and MCL were 35% and 29%, respectively.

Overall time to progression was 3.1 months, and the median duration of response for the 12 responders was 5.5 months, Dr. Reeder reported. Five patients were progression free at 6+ months, and 3 maintained a response at a median of 10.5 months (2.09 to 15.6+ months).

Grade 2 toxicities were hyperglycemia (16%) and hyperlipidemia (11%). Grade 3 toxicities included anemia (11%), neutropenia (16%), thrombocytopenia (30%), and hyperglycemia (11%). Grade 4 hyperlipidemia was reported in one patient (2%).

Dr. Reeder concluded, “The data offer proof of concept that targeting mTOR is clinically relevant in NHL.”

 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.